Free Cash Flow

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

The landmark partnership validates China's biotech prowess and injects Takeda's pipeline with next-gen cancer therapies, signaling a major industry shift.

Beyond marble floors, the new luxury is a seamless, secure, and AI-driven transaction. We explore how tech is reshaping high-end property deals.

After its DMD drug trial sent shares soaring over 370%, Capricor Therapeutics is raising $75M. A look at the high-stakes strategy to fund a breakthrough.

As REV Group preps its Q4 report, all eyes are on whether its booming specialty vehicle segment can offset volatility in the recreational vehicle market.

With AI creating a data center power crisis, one company's safer, greener nickel-zinc batteries are attracting major investment. Here's why it matters.

A recent tree care acquisition reveals a deeper strategy: private equity is building scale not just for profit, but to deploy AI and revolutionize work.